NEULANDLAB23,800.00

Neuland Laboratories Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABLAURUSLABSNHNATCOPHARMLALPATHLABSAILIFECOHANCEASTERDMMcap ₹30,703 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt82.5136.0196.6196.6
Net Debt-5.1-103.6119.9119.9
Total Debt/Equity0.060.090.100.10
Net Debt/Equity0.00-0.070.060.06
Total Debt/EBITDA0.180.420.340.34
Net Debt/EBITDA-0.01-0.320.210.16
Interest Coverage (EBIT/Interest)28.7831.0620.1620.16
Total Debt/Total Capital %6.048.199.499.49
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.